Maureen Testoni has been named as the 340B Health CEO by the e 340B Health board of directors.
The NCI Board of Scientific Advisors approved five Requests for Applications, as well as two Cancer Moonshot concepts, at a joint meeting with the National Cancer Advisory Board on Dec. 4, 2018.
I have had the privilege of accepting young men and women into medical oncology fellowship programs at Memorial Sloan Kettering Cancer Center, the University of Vermont Cancer Center and MD Anderson Cancer Center and I have watched many of them shine as they took on both academic and community oncology positions throughout the United States and the world.Waun Ki Hong was special.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
AstraZeneca and Merck said FDA has approved Lynparza for use as maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
FDA has expanded the indication for Sprycel (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia in combination with chemotherapy.
Merck said FDA has approved Keytruda for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, based on the results of the Cancer Immunotherapy Trials Network's CITN-09/KEYNOTE-017 trial.
Merck said FDA has extended the action date for the supplemental Biologics License Application for Keytruda as monotherapy for the first-line treatment of locally advanced or metastatic NSCLC in patients whose tumors express PD-L1 (tumor proportion score [TPS] ≥1%) without EGFR or ALK genomic tumor aberrations.
Merck said Keytruda (pembrolizumab), an anti-PD-1 therapy, has simultaneously received five new approvals from the Japan Pharmaceuticals and Medical Devices Agency, including three expanded uses in advanced non-small lung cancer, one in melanoma, as well as a new indication in advanced microsatellite instability-high tumors. The following new approvals were all granted priority review by the PMDA:
The Ministry of Health, Labour and Welfare of Japan has approved FoundationOne CDx as a comprehensive genomic profiling test for all solid tumors and a broad companion diagnostic for individuals living with advanced cancer.
